PRTN3 and rheumatoid arthritis: Since individuals with both ACPA and RF have a 10.5 times higher risk of developing RA than seronegative individuals4, researchers are currently focused on targeting individuals at risk of developing RA (the preclinical phase of RA) to delay or even prevent the onset of RA5.